Purpose of Review
During the last years, dupilumab, a fully human monoclonal antibody directed against the IL-4 receptor α subunit has been investigated in several clinical trials with respect to efficacy, tolerability, and safety in different atopic diseases such as atopic dermatitis, asthma, and chronic sinusitis with nasal polyposis. The aim of this review is to summarize this study data with focus on efficacy and safety.
Recent Findings
In atopic dermatitis, three original publications (in total six phase 1, 2, and 3 studies) report consistently about a till today not known high grade of efficacy reducing disease activity. Significant improvement of disease burden has been also seen in two publications on asthma (two phase 2 trials) as well as on chronic sinusitis with nasal polyposis (phase 2 trial). Remarkable is the safety profile with only moderately increased rates for mild or moderate nasopharyngitis and injection site reactions (erythema). Organ toxicities, an increased cardiovascular risk or other health risks have not been described so far. However, a moderate increase of the rate of conjunctivitis in trials on atopic dermatitis remains unclear.
Conclusion
The reviewed studies on various atopic diseases have shown that dupilumab is an innovative, highly efficient, well-tolerated biological drug and has the potential to become the first biological cytokine-directed drug to be authorized for atopic diseases such as atopic dermatitis or asthma. The safety profile seems to be unique with an extremely good tolerability as detected so far.